HR and breast cancer: A partitioned survival model was developed to compare costs and effectiveness of first-line (CDK4/6i-first) versus second-line (CDK4/6i-second) CDK4/6 inhibitor strategies among Chinese women with advanced HR+/HER2- breast cancer.